PHRR230831-006071
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
Merck Sharp & Dohme (I.A.) LLC·Phase 3·Philippine Health Research RegistrySuspended
Study focus
- Disease/Condition
- Carcinoma, Non-Small-Cell Lung
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Merck Sharp & Dohme (I.A.) LLC
- Location
- Australia;Brazil;Chile;China;Costa;Rica;Dominican;Republic;Germany;Greece;Guatemala;Israel;Italy;Jap
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Sep 22, 2023
- End date
- N/A
ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- Philippine Health Research Registry
- Trial ID
- PHRR230831-006071
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for PHRR230831-006071 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme (I.A.) LLC and is currently Suspended. The study focuses on Carcinoma, Non-Small-Cell Lung.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.